Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
March 13, 2024 16:01 ET
|
Spero Therapeutics, Inc.
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO,...
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
March 06, 2024 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments...
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
February 28, 2024 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
February 26, 2024 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2024 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments...
Spero Therapeutics Provides Corporate Update and 2024 Outlook
January 05, 2024 08:05 ET
|
Spero Therapeutics, Inc.
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI...
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
January 02, 2024 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
November 13, 2023 16:05 ET
|
Spero Therapeutics, Inc.
Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET...
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
November 06, 2023 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics to Present at Upcoming November Investor Conferences
November 01, 2023 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...